FDA Approves MiddleBrook’s Amoxicillin PULSYS For Pharyngitis/Tonsillitis In Adolescents And Adults
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, announced that it has received approval of its New Drug Application (NDA) from the U.S.
More: continued here
Filed under: Ear, Nose and Throat on January 29th, 2008